Twenty five patients with hyperprolactinaemia were treated with pergolide mesylate, a new dopamine receptor agonist. Twenty three received treatment for six to 20 months, and in all serum prolactin concentrations were considerably reduced. In most patients prolactin concentrations were maintained in the normal range by a low, once daily dose of pergolide and reversal of associated reproductive disorders was observed. Tumour volume as assessed by computed tomography decreased considerably during treatment in three out of four patients with a pituitary tumour. The drug was well tolerated. Side effects were similar to those of bromocriptine, but four out of eight patients who had been forced to stop taking bromocriptine because of untoward effects were subsequently able to tolerate treatment with pergolide.
Introduction
Pergolide mesylate (Lilly) is a synthetic ergoline derivative that suppresses secretion of prolactin in both subjects with hyperprolactinaemia and those with normal prolactin concentrations.1 -4 It is a potent dopamine receptor agonist that effectively lowers serum prolactin concentrations in patients with hyperprolactinaemia for at least 24 hours after a single dose. 3 Preliminary results of chronic administration of the drug to men and women with hypersecretion of prolactin suggested that pergolide would be a safe and successful means of treatment for such patients.3 Two patients who had been unable to tolerate treatment with bromocriptine were later maintained with pergolide. We now present the results of long term treatment in 25 patients, 22 of whom received treatment for six to 20 months.
Patients WOMEN (table)
Seventeen women (age 14-42) entered the study. Seven had radiological evidence of a pituitary tumour. Sixteen presented with amenorrhoea and one with irregular periods. Two wished to become pregnant. Eight of the amenorrhoeic patients had galactorrhoea and four also complained of vaginal dryness on intercourse. Two women suffered hot flushes. Eight patients had previously received bromocriptine, which had proved unsuccessful either because of unacceptable side effects or because the serum prolactin concentration was not adequately suppressed (as in one patient (case 6) oma and a serum prolactin concentration of 22 100 mU/1). Three women were forced to stop taking pergolide within two weeks after starting treatment because of persistent nausea; the remaining 14 were treated for six to 20 months.
MEN (table)
Eight men were included in the study; pituitary tumours had been diagnosed in seven. Five of these seven had previously undergone pituitary surgery but still had high serum prolactin concentrations; these five had remained hypogonadal after surgery but had evidence of gonadotrophin deficiency in addition to hyperprolactinaemia. They had all received testosterone replacement but despite normal serum concentrations of testosterone four of the five were not satisfied with their lack of response to treatment and complained, in particular, of lack of growth of facial hair. Two men (cases 18 and 20) presented with infertility and oligospermia. Sexual function in these two patients was otherwise normal, and we considered that the hyperprolactinaemia was probably a coincidental finding. Nevertheless, we thought it worth while to give them a trial of pergolide. One patient (case 25) had a visual field defect associated with a recurrent chromophobe adenoma of the pituitary. His serum prolactin concentration was only twice the upper limit of normal, and he almost certainly had a large "functionless" tumour rather than a prolactinoma, but we elected to give him a course of pergolide before considering more radical treatment. Two of the men with hypogonadism (cases 21 and 22) had considerable residual tumour tissue on computed tomography, and we were interested to see whether, in these patients too, pergolide would reduce the volume of the tumour. One man (case 24) had previously been treated with bromocriptine, which he had had to stop because of side effects.
METHODS
The once daily dosage schedule and the programme of investigation of patients receiving chronic treatment that we used were essentially those described previously4 and included regular measurement of serum concentrations of prolactin and gonadotrophins. We made one modification as a 25 ,ug capsule had become available. In the light of our preliminary assessment of the drug4 patients were given 25 jug initially and the dosage was increased at intervals of two weeks until effective suppression of prolactin was obtained. A biochemical profile for assessment of the results of liver function tests was monitored monthly. Ovulation was assessed by measurement of serum progesterone concentration in the mid-luteal phase of the menstrual cycle.
Results
Prolactin concentrations in the 17 women before treatment ranged from 880 to 24 100 mU/1 (upper limit of normal 480 mU/l) ( Clinical response was more difficult to judge in the men, but three out of four volunteered that their beard growth had increased while they were taking pergolide even though their androgen replacement treatment had not been changed.
In two men with prolactinomas (cases 21 and 22) the size of the tumour was reduced as judged by computed tomography during treatment (doses 500 ,eg and 200 jig a day, respectively). There was no obvious change on radiological assessment or by perimetry in the patient (case 25) with a visual field defect, but subsequent surgical exploration showed that the defect was related to fibrosis in the region of the optic chiasm and not to a direct effect of tumour tissue.
Effective suppression of prolactin concentrations in the two men with oligospermia (cases 18 and 20) had no effect on sperm density or fertility.
SIDE EFFECTS
The most common side effects were nausea (12 patients), nasal congestion (eight), and postural dizziness (eight); others were constipation (two), tiredness (two), and depression (one). In most patients the symptoms were mild and transient (particularly when the patients were started on a dose of 25 sLg daily) and were minimised by the patients taking the drug during a snack after retiring to bed. In three patients (cases 7, 8, and 11) nausea and postural dizziness were severe enough to force them to stop taking pergolide after only a few days' treatment (two had suffered a similarly severe reaction to bromocriptine), and three further patients stopped taking the drug after six to nine months' treatment: two (cases 1 and 24) complained of persistent nausea and drowsiness and the third (case 13) of depression.
Of the eight patients who had previously been treated with bromocriptine and in whom treatment had been stopped because of side effects, four, including the two described above, suffered the
same adverse symptoms while taking pergolide but the remaining four were able to tolerate long term treatment with pergolide. One of this last group (case 17) had suffered a rash while taking bromocriptine, which did not recur on pergolide. In all, six patients stopped taking pergolide because of side effects; four had suffered the same symptoms during previous treatment with bromocriptine (nausea in two (cases 7 and 8), drowsiness in one (case 24), and depression in one (case 13)), but two (cases 1 and 1 1), who both complained of nausea and drowsiness, experienced fewer problems when subsequently given bromocriptine and were able to continue long term treatment with this drug. As in our preliminary study, no patient had evidence of disturbed liver function while taking pergolide.
Discussion
Preliminary studies indicated the potential value of pergolide mesylate in treating hyperprolactinaemic states in women and men. ' 2 4 This long term study confirms the efficacy of a single, low, daily dose of pergolide in suppressing serum prolactin concentrations in hyperprolactinaemia. In most patients the effective dose is between 50 Lg and 150 ,ug daily.
As with bromocriptine, and in agreement with the findings of The standard biochemical test for pregnancy requires the detection of chorionic gonadotrophin, but it is insensitive and cannot be done within a few days of administration of chorionic gonadotrophin. Schwangerschafts protein 1 (SP,) is a protein produced by the placenta and secreted into the maternal bloodstream. Early work suggested that it might be a useful marker of pregnancy,' but this entailed measuring the protein by radioimmunoassay, which put it beyond the range of many laboratories. An easier enzyme immunoassay is now available.2 We applied this method to determining before the time of the first missed period whether a woman had conceived.
Patients, methods, and results
We took heparinised blood samples from 150 women attending an infertility clinic in Aberdeen. Seventy of the women received no treatment during the cycle under observation; 48 were treated with clomiphene citrate; 14 had ovulation induced with human menopausal gonadotrophin, and 12 were receiving bromocriptine. The remainder had undergone artificial insemination of donor semen. All patients were seen 21-32 days from their last period or, in the case of amenorrhoeic women, from the onset of treatment. All were in the luteal phase as judged by basal body temperature and plasma progesterone assay. In some the date of ovulation was pinpointed by determining the peak concentration of luteinising hormone and by ultrasonic scanning of the ovaries. In all patients the sample was taken, as far as we could determine, six to 14 days after ovulation. Serial samples were taken from patients under close observation. If all samples were negative for the protein they were taken as a single negative; if any were positive the patient was scored as being positive.
SP, was measured with an immunoassay kit (Behringwerke AG).2 The lower limit of sensitivity claimed by the manufacturers is 0 3 '4g/l. We operated a cut off point of 0 5 Atg/l.
Twenty six women yielded a concentration of the protein above 0-5 ,ug/l, the lowest value in this group being 1-8 ,Lg/l. All these women were later shown to be pregnant by a standard urinary haemagglutination pregnancy test and by ultrasonography. The table shows the clinical data on the patients.
The remaining 124 of the 150 patients tested yielded negative results. None was subsequently found to have been pregnant.
Comment
Although the number of cases examined was small, our findings suggest that assays of SP1 are a reliable pregnancy test and comparable with assays of P chorionic gonadotrophin. There were no false positive or false negative results, and the results are available on the
